Aktuelle Therapie des metastasierten Prostatakarzinoms

F. Sehn; A. S. Merseburger; G. von Amsberg

doi:10.1007/s11654-021-00310-2

Aktuelle Therapie des metastasierten Prostatakarzinoms

F. Sehn^*, A. S. Merseburger, G. von Amsberg

^*Korrespondierende/r Autor/-in für diese Arbeit

Klinik für Urologie

Abstract

The treatment of metastatic prostate cancer has made great progress during recent years and new substances have been introduced that significantly prolong patient survival. In this review, the authors aim to categorize recent data and approvals within the therapeutic landscape and provide an outlook on future therapeutic options.

Titel in Übersetzung	Current treatment of metastatic prostate cancer
Originalsprache	Deutsch
Zeitschrift	Best Practice Onkologie
Jahrgang	16
Ausgabenummer	6
Seiten (von - bis)	252-258
Seitenumfang	7
ISSN	0946-4565
DOIs	https://doi.org/10.1007/s11654-021-00310-2
Publikationsstatus	Veröffentlicht - 06.2021

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gesundheit und Wohlergehen

Strategische Forschungsbereiche und Zentren

Profilbereich: Lübeck Integrated Oncology Network (LION)

DFG-Fachsystematik

2.22-14 Hämatologie, Onkologie
2.22-08 Pharmazie
2.22-23 Reproduktionsmedizin, Urologie

Dokumente

10.1007/s11654-021-00310-2

Weitere Links

Link to publication in Scopus

Zitieren

@article{7ce972e89d4b4f2e86109c303accb53c,

title = "Aktuelle Therapie des metastasierten Prostatakarzinoms",

abstract = "The treatment of metastatic prostate cancer has made great progress during recent years and new substances have been introduced that significantly prolong patient survival. In this review, the authors aim to categorize recent data and approvals within the therapeutic landscape and provide an outlook on future therapeutic options.",

author = "F. Sehn and Merseburger, \{A. S.\} and \{von Amsberg\}, G.",

note = "Publisher Copyright: {\textcopyright} 2021, Springer Medizin Verlag GmbH, ein Teil von Springer Nature.",

year = "2021",

month = jun,

doi = "10.1007/s11654-021-00310-2",

language = "Deutsch",

volume = "16",

pages = "252--258",

journal = "Best Practice Onkologie",

issn = "0946-4565",

publisher = "Springer Medizin",

number = "6",

}

TY - JOUR

T1 - Aktuelle Therapie des metastasierten Prostatakarzinoms

AU - Sehn, F.

AU - Merseburger, A. S.

AU - von Amsberg, G.

PY - 2021/6

Y1 - 2021/6

N2 - The treatment of metastatic prostate cancer has made great progress during recent years and new substances have been introduced that significantly prolong patient survival. In this review, the authors aim to categorize recent data and approvals within the therapeutic landscape and provide an outlook on future therapeutic options.

AB - The treatment of metastatic prostate cancer has made great progress during recent years and new substances have been introduced that significantly prolong patient survival. In this review, the authors aim to categorize recent data and approvals within the therapeutic landscape and provide an outlook on future therapeutic options.

UR - https://www.scopus.com/pages/publications/85106689451

U2 - 10.1007/s11654-021-00310-2

DO - 10.1007/s11654-021-00310-2

M3 - Übersichtsarbeiten

AN - SCOPUS:85106689451

SN - 0946-4565

VL - 16

SP - 252

EP - 258

JO - Best Practice Onkologie

JF - Best Practice Onkologie

IS - 6

ER -

Aktuelle Therapie des metastasierten Prostatakarzinoms

Abstract

UN SDGs

Strategische Forschungsbereiche und Zentren

DFG-Fachsystematik

Dokumente

Weitere Links

Fingerprint

Zitieren